# Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

> **NCT01804634** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 60 (estimated)

## Conditions studied

- Refractory and/or Relapsed Metastatic Solid Tumors

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **RADIATION:** low dose total body irradiation
- **DRUG:** Melphalan
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01804634
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2013-03-27
- **Primary completion:** 2027-01
- **Final completion:** 2030-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01804634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01804634, "Reduced Intensity Haploidentical BMT for High Risk Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01804634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*